U.S. to Pause Distribution of J&J Vaccine Over Blood Clot Fears – NYT

imageStock Markets2 hours ago (Apr 13, 2021 12:07)

© Reuters.

By Geoffrey Smith 

Investing.com — The U.S. is to suspend the distribution of Johnson & Johnson (NYSE:JNJ)’s Covid-19 vaccine due to fears of linkages to rare blood clotting problems, the New York Times reported on Tuesday. 

Officials at both the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration have subsequently confirmed that they have recommended the pause in the use of J&J’s vaccine, due to “abundance of caution.”

At 7:25 AM ET (1225 GM), J&J stock fell 2.8% premarket.

The news is a setback for the U.S.’s national vaccination campaign, which had factored the availability of J&J’s drug into its ambitions to have the entire U.S. adult population eligible for vaccination already this month.

Over seven million shots of the J&J vaccine have been distributed so far in the U.S. According to the NYT, there have been six cases of people developing blood clots on the brain within two weeks of receiving the shot. All those affected have been women between the ages of 18 and 48, it noted.

This news follows similar issues with AstraZeneca (NASDAQ:AZN)’s Covid-19 vaccine, which resulted in a number of countries in Europe as well as Canada and Australia pausing the use of the U.K.-Swedish drugmaker’s shot. The medical authorities in the U.K. and Europe found a possible link to very rare cases of unusual blood clots with low blood platelets after studying the data, but decided that the overall benefit was still worth the risk.

U.S. to Pause Distribution of J&J Vaccine Over Blood Clot Fears – NYT

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave A Reply

Your email address will not be published.